Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5267683 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| RO5267683 | DRUG | Multiple ascending doses |
| placebo | DRUG | Multiple ascending doses |
Inclusion Criteria: * Healthy male and female subjects, 18 to 45 years of age, * Body mass index (BMI) 18 to 30 kg/m2 inclusive, and a minimum weight of 50 kg at screening * Female subjects must be surgically sterile or post-menopausal * Male subjects must use a barrier method of contraception for ...
RO5267683 is an investigational small molecule developed by Roche Holding AG. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been disclosed, and it remains in early clinical development.
RO5267683 is being developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical program for this investigational small molecule.
RO5267683 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The program has completed one Phase 1 trial, and no active trials are currently listed.
RO5267683 has been evaluated in one clinical trial, NCT01398241, titled A Study of RO5267683 in Healthy Subjects. This completed Phase 1 trial enrolled 38 healthy adult volunteers in France. It was randomized, double-blind, and placebo-controlled.
RO5267683 is an investigational drug, and the specific indication it is being developed to treat has not been disclosed. Its only reported clinical study was conducted in healthy volunteers rather than in patients with a defined disease.
The Phase 1 trial of RO5267683, NCT01398241, was a randomized, double-blind, placebo-controlled study in healthy subjects. It enrolled 38 participants of all sexes, aged 18 years and older, at sites in France. The trial has been completed.